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Abstract
Background: This study aimed to investigate the clinical significance of contrast enhanced ultrasound (CEUS) in
diagnosis of benign prostatic hyperplasia (BPH) through comparing CEUS parameters between BPH and normal
person.
Methods: A retrospective study of sixty BPH patients (aged 73.5 ± 20.5 years old) and thirty normal controls without
prostate diseases (aged 75.3 ± 19.7 years old) who had accepted CEUS detection were performed. Time-intensity
curves were obtained for all tests in regions of interest. Images were processed using ACQ software and the
following parameters were obtained: arrival time (AT), peak intensity (P), time to peak (TP), area under the curve
(AUC), mean transit time (MTT) and extinction time (ET). Differences in inner and outer gland of prostate between
BPH and the normal tissue were evaluated.
Results: There was a clear boundary between the inner and outer gland of BPH prostate. AT, TP, MTT, ET and P in
BPH outer gland were significantly higher than the control group. In inner gland, MTT, ET, AUC and P were also
significantly higher than the controls. The accurate rate to diagnose BPH using CEUS was 95.6%, and the sensitivity
and specificity were 95.0% and 96.7%, respectively.
Conclusions: Among these significantly changed parameters, the increases of MTT, ET and AUC in inner gland and
AT, TP in outer gland were most likely related to BPH. These parameters provide an objective visual assessment to
diagnosis of BPH.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/4852383312229155
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Background
Benign prostatic hyperplasia (BPH) is one of the most
common benign neoplasms in aging males. Nowadays,
with the increased population of aging male, the inci-
dence rate of BPH is also raised [1]. According to epi-
demiology researches, a dramatic rise in BPH is found in
males over the age of 40 and the incidence reached to
50% and 80% in the age of 60 and 80, respectively [2].
Prostate is an abundant blood supply organ and divided
into inner and outer gland [3]. The inner gland of
prostate (including urethra periurethral zone and transi-
tional areas) is the most predilection site of BPH and
sensitive to sex hormone; On the contrary, the outer
gland (including central zone and peripheral region) has
a lower risk and is insensitive [4].
Nowadays, ultrasonic examination is the most com-
mon diagnostic method in BPH. In ultrasonic images,
the inner and outer gland of prostate in BPH patients
can be clearly observed. Besides, the volume of inner
gland in BPH patients is increased significantly, while
the outer gland is pressurized to be smaller [5]. Contrast
enhanced ultrasound (CEUS) is a technology developed
rapidly in recent years. CEUS detection is considered to
be an effective and accurate method in BPH diagnosis
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because of the parameters which make the diagnosis to
be visual and objective by distinguishing between normal
and hyperplastic tissues [6]. In CEUS, contrast agent is
used to enhance the contrast of tissues and blood within
the body in medical imaging. The contrast agent greatly
improves the sensitivity and accuracy of ultrasound to de-
tect the tissue perfusion [7,8]. Therefore, contrast agent
significantly increases the diagnostic potential of CEUS
and makes it possible to visualize tumor vascularization
[7,8]. Besides, CEUS images have a high spatial and tem-
poral resolution. Several researches have certified this
technology has a potential in diagnosis of liver, prostate
and other visceral organs tumor [9-12]. But there are
few studies on comparison of CEUS in normal prostate
and BPH.
In this research, a second-generation ultrasound con-
trast agent of SonoVue was used to detect ultrasound
contrast time-intensity curve in inner and outer gland.
The differences and correlations between BPH and




Sixty BPH patients treated by CEUS at Central Hospital
of Shanghai Jiading District from May 2009 to October
2012 were studied retrospectively. All of them did not
have had prostate surgery and associated with urinary
frequency, urinary urgency, or dysuria. Among them, 34
cases were associated with urine retention. They were
confirmed not prostate cancer sufferers by transrectal
needle biopsy in inner and outer gland. Thirty healthy
aging male volunteers without prostate diseases were se-
lected as the normal controls. The age, weight, body
mass index (BMI), prostate specific antigen (PSA), hyper-
tension, coronary heart diseases, diabetes and other
medical history were recorded (Table 1). All people in
the research were told the possible complications of the
examination, and signed informed consent. This study
was approved by the Shanghai Jiading District Central
Hospital Ethics Committee.
Research methods
SonoVue (Bracco, Italy), as the contrast agent was mixed
with 5 ml physiological saline before a bolus injection of
1 ml mixture to the testing people via ulnar vein. Then a
rapid bolus of 5 ml SonoVue-saline mixture was injected
to the testing people. Video record was started to detect
the contrast agent with time synchronization. The con-
tinuing observation was recorded until SonoVue com-
pletely subsided. The patient was supine, and CEUS
detection was conducted in a cross-section through ab-
domen with ultrasound diagnostic apparatus (PHILIPS
IU22) at probe frequency 2.5-5.0 MHz and mechanical
index 0.06.
After CEUS, contrast parameters including arrival time
(AT), peak intensity (P), time to peak (TP), area under
the curve (AUC), mean transit time (MTT) and extinc-
tion time (ET) were analyzed by the ACQ software.
Three regions of interest (ROI) of each inner and outer
gland were isolated by oval-shaped tracings. The inten-
sity distribution of contrast agent pixels in ROI was used
for quantitative analysis, and the mean value in these
three ROI was calculated. Besides, a contrast time-intensity
curve was also processed. To analyze the CEUS data and
make a diagnosis, a single blind method was carried out
by 2 experienced examiners. A third experienced exam-
iner was invited to evaluate the data when there was any
disagreement.
Data analysis
The data were expressed as mean ± standard deviation
(SD). Statistical analyses were performed with SPSS 13.0
(SPSS Inc., Chicago, USA). Significant differences of
contrast parameters between two groups were detected
with T test. p < 0.05 was considered as significant. p < 0.01
was considered as highly significant.
Results
Basic information of patients
The age of the BPH patients and the controls were respect-
ively 73.5 ± 20.5 years old (n = 60) and 75.3 ± 19.7 years
old (n = 30) in the present study. There were no significant
difference between the controls and BPH patients in terms
of age, body weight, BMI, hypertension, diabetes and cor-
onary heart diseases, but a significant difference in PSA
between the two groups (Table 1). According to statistics
in BPH patients, the international prostate symptom score
(IPSS) was 25.5 ± 4.9, the quality of life score (QOL) was
5.1 ± 0.7, the prostate volume (PV) was 50.6 ± 3.9 ml, the
residual urine volume (RUV) was 150.8 ± 47.9 ml, and the
maximum urinary flow rate (Qmax) was 8.8 ± 3.3 ml/s.
CEUS results of the control group and BPH group
CEUS diagnosis in normal prostate and BPH prostate
were carried out. Figure 1 showed the CEUS images and
Table 1 Comparison of baseline data between control






Age(year) 75.3 ± 19.7 73.5 ± 20.5 >0.05
Body weight (Kg) 65.7 ± 10.4 68.5 ± 11.3 >0.05
BMI 22.8 23.2 >0.05
PSA(ng/ml) 2.4 12.6 <0.05
Hypertension(%) 25.7 26.5 >0.05
Diabetes (%) 10.5 9.7 >0.05
Coronary heart disease (%) 13.7 15.4 >0.05
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the contrast time-intensity curves of the normal prostate
and BPH prostate, respectively. Table 2 indicated accur-
ate parameters in normal and BPH prostate.
In control group, AT in outer gland was a little shorter
than that in inner gland, while the enhanced pattern of
inner and outer gland was similar, filling from the periph-
eral region to the central zone; In 86.7% control group, TP
in outer gland was significant shorter than that in the
inner gland (p < 0.01) and P was also significant lower
than the inner gland (p < 0.01); ET of the outer gland was
shorter than the inner gland without significant difference,
the disappeared pattern in outer gland was from central
zone to peripheral region. In inner gland, SonoVue was
disappeared from peripheral region to urethra periurethral
Figure 1 Ultrasound Contrast image and contrast time-intensity curve of normal and A, inner gland in normal; B, Outer gland in
normal A1, inner gland in BPH prostate; B1, Outer gland in BPH prostate.
Table 2 Data and analyze results of BPH and control group
BPH group Control group
Inner gland Outer gland Inner gland Outer gland
AT(s) 26.55 ± 2.29 30.84 ± 4.32☆☆ 27.26 ± 2.10 24.81 ± 2.55
P(%) 53.35 ± 7.70**# 36.38 ± 7.20☆ 44.06 ± 2.57** 25.74 ± 6.87
TP(s) 65.69 ± 19.58 58.42 ± 8.48☆☆ 52.78 ± 4.09** 37.16 ± 8.09
AUC(%s) 6135.47 ± 1706.70**## 2969.80 ± 1369.06 3987.50 ± 219.66** 1993.69 ± 933.34
MTT(s) 98.27 ± 9.12**## 77.02 ± 8.50☆ 76.21 ± 3.10* 59.53 ± 14.74
ET(s) 194.89 ± 44.97## 159.21 ± 36.04☆ 127.94 ± 14.52 124.04 ± 13.83
*represents p < 0.05 when data of inner gland compared to the outer gland in the same group (**means p < 0.01); #represents p < 0.05 when inner gland of BPH
group compared to the inner gland of Control group (##means p < 0.01); ☆represents p < 0.05 when outer gland of BPH group compared to the outer gland of
Control group (☆☆means p < 0.01).
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zone; AUC in the outer gland in 93.3% control group was
significantly smaller than the inner gland (p < 0.01) and
MTT was shorter (p < 0.05).
In BPH group, the result was different. AT in inner
gland was shorter than that in outer gland, but the dif-
ference was not significant (p > 0.05). The enhanced pat-
tern of inner gland was filling from capsule and urethra
periurethral zone to peripheral region, while the outer
gland was from capsule to the central zone, there was a
clear boundary between the inner and outer gland; TP in
inner and outer gland was similar(p < 0.01), but P of
inner gland was significant higher than the outer gland
in 85.0% BPH (p < 0.01); ET of the inner gland was longer
than that of the outer gland without significant difference,
and the SonoVue in inner gland was disappeared from the
peripheral region to urethra periurethral zone. Besides,
the disappeared pattern in outer gland was uniformly;
AUC in 91.7% BPH group exhibited inner gland was sig-
nificantly larger than the outer gland (p < 0.01) and MTT
was longer (p < 0.01).
Comparison of CEUS parameters in the control group and
BPH group
The CEUS parameters between the BPH and control
group were compared (Table 2). In inner gland, there
was no significant difference in AT and TP, while signifi-
cant differences were found in P, AUC, MTT and ET.
Compared to the control, the P was significant stronger
in BPH group (p < 0.05). Besides, the AUC, MTT and ET
were significantly higher in BPH group (p < 0.01). In outer
gland, the AT and TP of BPH were highly significantly
longer than the control group (p < 0.01); the P, MTT and
ET increased significantly in BPH group (p < 0.05). Al-
though the AUC was also a bit larger in BPH, but the dif-
ference was not significant (p > 0.05).
The diagnostic accuracy
According to the comprehensive analysis of the contrast
images and parameters, one case was misdiagnosed to
be BPH and three atypical lesions were misdiagnosed to
be normal. According to statistics, to diagnose BPH with
CEUS, the accurate rate was 95.6% (86/90), the sensitivity
was 95.0% (57/60) and the specificity was 96.7% (29/30).
Discussion
CEUS is a new technology developed rapidly in recent
years and beneficial for improving the diagnostic accur-
acy. SonoVue, a second-generation ultrasound contrast
agent, which consists of stabilized microbubbles of a
sulphur hexafluoride with remarkable properties [13], is
used in this study. It can pass the capillary bed and show
the microcirculation [14]. Besides, SonoVue can enhance
the echo contrast of blood flow in tissues and conveni-
ently detect the lesion and surrounding tissue perfusion
changes through the real-time dynamic observation of
the CEUS [15,16]. It is often recommended for a dosage
of 2.4 ml [17] or more [18]. In this study, we found 1 ml
SonoVue mixture was enough to form a clearly contrast
image.
BPH usually occurres in the inner gland of prostate
and its pathogenesis is complicated. It is found that the
expression levels of angiogenic growth factors (such as
vascular endothelial growth factor) in the urine of BPH
patients are significantly higher than normal levels,
which suggests that angiogenesis is closely related to the
incidence of BPH [19,20]. As we know, the main blood-
supplied artery for the prostate is bladder artery branched
from the internal iliac artery. The bladder artery branches
into prostate capsule artery and urethral artery at the
junction of the bladder and prostate, which supplies blood
to the main part of outer and inner prostate gland, separ-
ately [21]. According to the study on radical prostatec-
tomy specimens, the microvessel density in tuberal area is
significantly increased in BPH, which prompts that the
formation and development of BPH nodules needs in-
creased blood supply [22,23]. Besides, researchers also
found abundant neovascularizations were regenerated in
BPH gland tissue. Microcirculation in the outer gland is
relatively decreased due to increased perfusion pressure
from inner gland [22]. In this study, the enhanced pattern
in BPH prostate begun to increase in the inner gland and
followed by the outer gland, while the disappearance situ-
ation was reverse. In addition, significant differences in
CEUS parameters between the inner and outer gland were
consistent with the former researches [24]. And the P,
MTT and ET in inner gland were also longer than the
outer gland. These results are closely consistent with the
feeding arteries in gland, and indicate CEUS can reflect
the distribution and blood flow direction of vascular in
BPH accurately and clearly.
When compared with the normal prostate through
CEUS, the blood supply of both inner and outer gland
in BPH prostate was abundant. This result suggests that
not only in the inner gland, the outer gland also have
different degrees of proliferation in BPH. Therefore,
when CEUS is used to diagnosis the BPH, the inner and
outer gland and its corresponding tissue should be com-
pared carefully in order to obtain a scientific and real
conclusion. On the other hand, the high level of accur-
acy, sensitivity and specificity rate of CEUS in diagnosis
of BPH further proves that CEUS is an effective means
in diagnosis of BPH. However, none of the imaging
methods can be regarded as reliable enough on its own,
careful attention must to be paid to delicate situations.
Prostate biopsy of the biomarkers [25] combined with an
entropy-based automated approach to ROI segmentation
[26] may provide benefit for diagnosis of BPH or prostate
cancer. What’s more, the sample size in the present study
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is not large enough, so a retrospective study based on lar-
ger sample size is needed to confirm the findings in this
study in future.
Conclusions
In conclusion, the information of BPH can be reflected
clearly by CEUS parameters. The perfusion condition of
contrast agent can indicate the hemodynamic information
of the organ which is highly correlated with BPH.
Moreover, CEUS can be used to diagnose BPH with a
high accuracy, sensitivity and specificity.
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